tripelennamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2762 | 91-81-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat ASTHMA; HAY FEVER; URTICARIA; and RHINITIS; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.15 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 2.84 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 19, 1948 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D04AA04 | DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use |
| ATC | R06AC04 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted ethylene diamines |
| MeSH PA | D018926 | Anti-Allergic Agents |
| MeSH PA | D018494 | Histamine Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dermatographic urticaria | indication | 7632005 | DOID:743 |
| Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
| Allergic rhinitis | indication | 61582004 | |
| Nasal discharge | indication | 64531003 | |
| Nasal congestion | indication | 68235000 | |
| Sneezing | indication | 76067001 | |
| Urticaria | indication | 126485001 | |
| Itching of skin | indication | 418363000 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Anaphylaxis Adjunct | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Antihistaminic therapy | Indication |
| Cattle | Antihistaminic therapy | Indication |
| Dogs | Antihistaminic therapy | Indication |
| Horses | Antihistaminic therapy | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| RE-COVR | Kinetic Technologies LLC | 1 |
| Tripelennamine Hydrochloride Injection | Huvepharma EOOD | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.62 | Basic |
| pKa2 | 4.33 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | IC50 | 7.40 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019963 | VUID |
| N0000148048 | NUI |
| D02091 | KEGG_DRUG |
| 6138-56-3 | SECONDARY_CAS_RN |
| 154-69-8 | SECONDARY_CAS_RN |
| 4018394 | VANDF |
| 4018395 | VANDF |
| 4019963 | VANDF |
| C0041090 | UMLSCUI |
| CHEBI:9741 | CHEBI |
| CHEMBL1241 | ChEMBL_ID |
| DB00792 | DRUGBANK_ID |
| CHEMBL1200446 | ChEMBL_ID |
| CHEMBL151676 | ChEMBL_ID |
| D014309 | MESH_DESCRIPTOR_UI |
| 5587 | PUBCHEM_CID |
| 7318 | IUPHAR_LIGAND_ID |
| 1548 | INN_ID |
| 3C5ORO99TY | UNII |
| 10847 | RXNORM |
| 3076 | MMSL |
| 5638 | MMSL |
| d00781 | MMSL |
| 003374 | NDDF |
| 003375 | NDDF |
| 003376 | NDDF |
| 25014009 | SNOMEDCT_US |
| 373475006 | SNOMEDCT_US |
| 53405009 | SNOMEDCT_US |
| CHEMBL1200769 | ChEMBL_ID |
Pharmaceutical products:
None